AI-powered drug discovery startup LabGenius has secured GBP 35 million (USD 44.5 million) in a Series B funding round led by M Ventures. Existing investors Atomico and Kindred Capital and new investors Octopus Ventures and LG Corp also participated in the round.
The funds are planned to be used to broaden the scope of the company’s ML-powered discovery platform and advance its wholly-owned pipeline of multispecific antibodies to the clinical stage. Following the success of a recent research collaboration with Sanofi, the expanded platform is expected to enable broader strategic partnerships across various therapeutic areas.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.